Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
Total Valuation
Bolt Biotherapeutics has a market cap or net worth of $12.41M. The enterprise value is -$2.41M.
Market Cap$12.41M
Enterprise Value-$2.41M
Share Statistics
Bolt Biotherapeutics has 38.34M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38.34M
Owned by Insiders11.08%
Owned by Instutions41.67%
Financial Efficiency
Bolt Biotherapeutics’s return on equity (ROE) is -1.10 and return on invested capital (ROIC) is -84.91%.
Return on Equity (ROE)-110.35%
Return on Assets (ROA)-63.35%
Return on Invested Capital (ROIC)-84.91%
Return on Capital Employed (ROCE)-87.19%
Revenue Per Employee$147,884.615
Profits Per Employee-$1,213,807.692
Employee Count52
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bolt Biotherapeutics is -0.32. Bolt Biotherapeutics’s PEG ratio is 0.03.
PE Ratio-0.32
PS Ratio2.66
PB Ratio0.36
Price to Fair Value0.36
Price to FCF-0.33
Price to Operating Cash Flow-0.33
PEG Ratio0.03
Income Statement
In the last 12 months, Bolt Biotherapeutics had revenue of $7.69M and earned -$63.12M in profits. Earnings per share was -$1.66.
Revenue$7.69M
Gross Profit-$8.20M
Operating Income-$73.05M
Pretax Income-$63.12M
Net Income-$63.12M
EBITDA-66.45M
Earnings Per Share (EPS)-1.66
Cash Flow
In the last 12 months, operating cash flow was -$61.29M and capital expenditures -$41.00K, giving a free cash flow of -$61.33M billion.
Operating Cash Flow-$61.29M
Free Cash Flow-$61.33M
Free Cash Flow per Share-$1.60
Dividends & Yields
Bolt Biotherapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-300.16%
Earnings Yield-308.91%
Stock Price Statistics
Beta0.70
52-Week Price Change-67.26%
50-Day Moving Average0.43
200-Day Moving Average0.58
Relative Strength Index (RSI)45.16
Average Volume (3m)136.76K
Important Dates
Bolt Biotherapeutics upcoming earnings date is May 8, 2025, After Close.
Last Earnings DateMar 24, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Bolt Biotherapeutics as a current ratio of 3.20, with Debt / Equity ratio of 0.44
Current Ratio3.20
Quick Ratio3.20
Debt to Market Cap1.23
Net Debt to EBITDA-0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bolt Biotherapeutics has paid $414.72K in taxes.
Income Tax$414.72K
Effective Tax Rate0.00%
Enterprise Valuation
Bolt Biotherapeutics EV to EBITDA ratio is -0.58, with an EV/FCF ratio of -0.63.
EV to Sales5.00
EV to EBITDA-0.58
EV to Free Cash Flow-0.63
EV to Operating Cash Flow-0.63
Balance Sheet
Bolt Biotherapeutics has $47.32M in cash and marketable securities with $25.21M in debt, giving a net cash position of -$22.11M billion.
Cash & Marketable Securities$47.32M
Total Debt$25.21M
Net Cash-$22.11M
Net Cash Per Share-$0.58
Tangible Book Value Per Share$1.50
Margins
Gross margin is 100.00%, with operating margin of -949.91%, and net profit margin of -820.78%.
Gross Margin100.00%
Operating Margin-949.91%
Pretax Margin-820.78%
Net Profit Margin-820.78%
EBITDA Margin-864.17%
EBIT Margin-887.33%
Analyst Forecast
The average price target for Bolt Biotherapeutics is $1.13, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.13
Price Target Upside253.12%
Analyst ConsensusHold
Analyst Count4
Revenue Growth Forecast-2.36%
EPS Growth Forecast9.68%